Test Price
2,100 AED✅ Home Collection Available
Amniotic Fluid Molecular Karyotyping Test in UAE | 2100 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189 & ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Telephonic Post-Test Genetic Counseling with our DHA-licensed clinical genetics team for result interpretation and prenatal management.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 (Arabic/English).
Test Overview & Methodology
The Amniotic Fluid Molecular Karyotyping Test (also referred to as prenatal chromosomal microarray or high-resolution karyotype) detects submicroscopic deletions, duplications, and aneuploidies from cultured amniocytes using advanced molecular cytogenetics and culture-based karyotyping. In the UAE, it is the definitive invasive prenatal diagnostic procedure for fetal genetic conditions, offering comprehensive genomic coverage beyond standard G-banded karyotyping. This assay identifies pathogenic copy number variants (CNVs) as small as 50 kb, providing critical information for managing high-risk pregnancies.
| Feature | Our Test (Molecular Karyotyping) | Standard Karyotype (G-Banding) |
|---|---|---|
| Resolution | ≥ 50 kb (detects microdeletions/duplications) | 5–10 Mb (large structural anomalies only) |
| Methodology | Cell Culture + Chromosomal Microarray (CMA) / aCGH, confirmed by karyotyping | Cell Culture + Giemsa Banding & Microscopy |
| Turnaround Time | 7–9 Days | 14–21 Days |
| Diagnostic Yield | Increases detection of pathogenic CNVs by ~6% over karyotype in fetuses with structural anomalies | Lower resolution; misses many microdeletion syndromes |
Physician Insight & Safety Protocols
“As a DHA-licensed Consultant in Medical Genetics, I emphasize that molecular karyotyping of amniotic fluid provides unparalleled resolution for detecting clinically significant copy number variants that standard karyotyping would miss. However, results must be interpreted within the full clinical context including detailed fetal ultrasound, maternal history, and biochemical screening. A negative result reduces but does not eliminate the possibility of a genetic disorder; post-test genetic counseling is strongly recommended to ensure informed decision-making for prenatal care.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Notice: Medication & Procedural Safety
Important: Do not stop, adjust, or begin any medication or prenatal supplement without explicit approval from your managing obstetrician. Agents such as aspirin, therapeutic anticoagulants, antiplatelet drugs, or immunosuppressants may elevate the risk of bleeding or complications during amniocentesis. A complete medication review must be conducted prior to the procedure to ensure maternal and fetal safety.
Exclusion Criteria & Emergency Red Flags
- Active vaginal bleeding or ruptured membranes (contraindication for amniocentesis).
- Maternal fever >38.5°C or acute infectious illness prior to procedure.
- Severe oligohydramnios (amniotic fluid index <5 cm) precluding safe tap.
- Known maternal coagulopathy or use of therapeutic anticoagulation without bridging plan.
- Seek emergency care if: post-procedure you experience severe abdominal pain, persistent leaking of fluid, fever, or contractions.
Patient FAQ & Clinical Guidance
1. Why is molecular karyotyping on amniotic fluid recommended instead of NIPT?
Molecular karyotyping of amniotic fluid provides a definitive diagnosis of submicroscopic chromosomal abnormalities that non-invasive prenatal testing (NIPT) cannot detect, with nearly 100% accuracy. NIPT is a screening test that only flags common trisomies, while this invasive test analyzes cultured fetal cells to uncover hundreds of pathogenic microdeletions and duplications, giving you a complete genomic picture for informed decision-making.
2. How safe is amniocentesis in a UAE-accredited facility, and what is the miscarriage risk?
When performed by an experienced DHA-licensed specialist under continuous ultrasound guidance, the procedure-related miscarriage risk is less than 1 in 900, making it exceptionally safe. Our network follows Federal Decree-Law No. 4 of 2016 on Medical Liability and strict aseptic protocols using a single 22G spinal needle with continuous fetal monitoring. All samples are processed in ISO 15189-accredited cytogenetics laboratories to ensure diagnostic reliability.
3. Will my health insurance cover this, and how do you protect my genetic data?
Most UAE insurance plans cover molecular karyotyping for amniotic fluid when medically indicated (e.g., advanced maternal age, abnormal ultrasound, or positive screening), and we offer direct billing verification. Your genetic data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and stored on encrypted servers with strict access controls; only your designated physician receives the report, and no genomic data is shared without explicit consent.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License Number 1143 and adheres to the highest standards of data protection and clinical governance. All patient information and genetic data are processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical procedures and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring that your rights, privacy, and safety are protected throughout the testing journey.
Clinical & Logistical Metadata
| Test Name | Amniotic Fluid Molecular Karyotyping (Prenatal Chromosomal Microarray) |
| Price (AED) | 2,100 |
| Turnaround Time | 7–9 Business Days |
| Sample Type / Matrix | Amniotic Fluid (Hospital Extraction Only – sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety) |
| Methodology Used | Cell Culture + Chromosomal Microarray (CMA / aCGH) with G-Banded Karyotype Confirmation |
| ICD-10-CM Code | Z36.8 |
| LOINC Code | 81272-4 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians